Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Hsiao, Wesley Wei-Wen | Angela, Stefanny | Le, Trong-Nghia | Ku, Chia-Chi | Hu, Po-Sheng | Chiang, Wei-Hung
Article Type: Review Article
Abstract: Alzheimer’s disease (AD) is a pathological disorder defined by the symptoms of memory loss and deterioration of cognitive abilities over time. Although the etiology is complex, it is mainly associated with the accumulation of toxic amyloid-β peptide (Aβ) aggregates and tau protein-induced neurofibrillary tangles (NFTs). Even now, creating non-invasive, sensitive, specific, and cost-effective diagnostic methods for AD remains challenging. Over the past few decades, polymers, and nanomaterials (e.g., nanodiamonds, nanogold, quantum dots) have become attractive and practical tools in nanomedicine for diagnosis and treatment. This review focuses on current developments in sensing methods such as enzyme-linked immunosorbent assay (ELISA) and …surface-enhanced Raman scattering (SERS) to boost the sensitivity in detecting related biomarkers for AD. In addition, optical analysis platforms such as ELISA and SERS have found increasing popularity among researchers due to their excellent sensitivity and specificity, which may go as low as the femtomolar range. While ELISA offers easy technological usage and high throughput, SERS has the advantages of improved mobility, simple electrical equipment integration, and lower cost. Both portable optical sensing techniques are highly superior in terms of sensitivity, specificity, human application, and practicality, enabling the early identification of AD biomarkers. Show more
Keywords: Alzheimer’s disease, amyloid-β , ELISA, nanomaterials, optical analysis platform, polymers, SERS, tau protein
DOI: 10.3233/JAD-221202
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 821-845, 2023
Authors: Liu, Rui | Zhang, Lei | You, Hao
Article Type: Review Article
Abstract: The pathogenesis of Alzheimer’s disease (AD) is complicated and involves multiple contributing factors. Mounting evidence supports the concept that AD is an age-related metabolic neurodegenerative disease mediated in part by brain insulin resistance, and sharing similar metabolic dysfunctions and brain pathological characteristics that occur in type 2 diabetes mellitus (T2DM) and other insulin resistance disorders. Brain insulin signal pathway is a major regulator of branched-chain amino acid (BCAA) metabolism. In the past several years, impaired BCAA metabolism has been described in several insulin resistant states such as obesity, T2DM and cardiovascular disease. Disrupted BCAA metabolism leading to elevation in circulating …BCAAs and related metabolites is an early metabolic phenotype of insulin resistance and correlated with future onset of T2DM. Brain is a major site for BCAA metabolism. BCAAs play pivotal roles in normal brain function, especially in signal transduction, nitrogen homeostasis, and neurotransmitter cycling. Evidence from animal models and patients support the involvement of BCAA dysmetabolism in neurodegenerative diseases including Huntington’s disease, Parkinson’s disease, and maple syrup urine disease. More recently, growing studies have revealed altered BCAA metabolism in AD, but the relationship between them is poorly understood. This review is focused on the recent findings regarding BCAA metabolism and its role in AD. Moreover, we will explore how impaired BCAA metabolism influences brain function and participates in the pathogenesis of AD. Show more
Keywords: Alzheimer’s disease, branched-chain amino acids, insulin resistance, metabolic neurodegenerative disease, metabolism
DOI: 10.3233/JAD-221147
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 847-862, 2023
Authors: Zhang, Kexin | Du, Xinzhe | Gao, Yao | Liu, Sha | Xu, Yong
Article Type: Review Article
Abstract: As the size of the population aged 65 and older continues to grow, the incidence and mortality rates of Alzheimer’s disease (AD) are increasing annually. Unfortunately, current treatments only treat symptoms temporarily and do not alter the patients’ life expectancy or course of AD. Mesenchymal stem cells (MSCs) have shown a certain therapeutic potential in neurodegenerative diseases including AD due to their neuroinflammatory regulation and neuroprotective effects. However, the low survival and homing rates of MSCs after transplantation seriously affect their therapeutic effectiveness. Therefore, appropriate in vitro preconditioning is necessary to increase the survival and homing rates of MSCs …to improve their effectiveness in treating AD. Here we summarize the therapeutic mechanisms of MSCs in AD and the chemical reagents used for the pretreatment of MSCs. Show more
Keywords: Alzheimer’s disease, mesenchymal stem cell, neuroinflammation, neuroprotection, pretreatment
DOI: 10.3233/JAD-221253
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 863-878, 2023
Authors: Nijskens, Charlotte | Henstra, Marieke | Rhodius-Meester, Hanneke | Yasar, Sevil | van Poelgeest, Eveline | Peters, Mike | Muller, Majon
Article Type: Review Article
Abstract: The number of people living with dementia, such as Alzheimer’s disease, is increasing worldwide. Persons with dementia often have a high risk of atherosclerotic cardiovascular disease and they are therefore theoretically eligible for treatment of hypertension and hyperlipidemia. However, in this population, beneficial and harmful effects of cardiovascular risk management (CVRM) may be different compared to older persons without cognitive impairment. Current CVRM guidelines are based on trials from which persons with dementia were excluded. In this narrative review, we will discuss how current guidelines can be translated to persons with dementia and which aspects should be taken into account …when treating hypertension and hyperlipidemia to prevent major adverse cardiovascular events (MACE). Survival time is significantly shorter in persons with dementia. We therefore suggest that since the main goal of CVRM is prevention of MACE, first of all, the patient’s life expectancy and treatment wishes should be evaluated. Risk assessment tools are to be used with care, as they tend to overestimate the 5- and 10-year risk of MACE and benefit from CVRM in the prevention of MACE in persons with dementia. When the clinician and patient have decided that treatment is initiated or intensified, patients should be closely monitored since they are at high risk for adverse drugs events and overtreatment due to the natural course of blood pressure in persons with dementia. In the event of intolerance or side effects, medication should be switched or withdrawn. For persons with dementia and limited life expectancy, deprescribing should be part of usual care. Show more
Keywords: Alzheimer’s disease, cardiovascular diseases, cardiovascular risk, control, dementia, hypercholesterolemia, hypertension, prevention
DOI: 10.3233/JAD-230019
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 879-889, 2023
Authors: Bauernschmidt, Dorothee | Hirt, Julian | Langer, Gero | Meyer, Gabriele | Unverzagt, Susanne | Wilde, Fabian | Wittmann, Janina | Bieber, Anja
Article Type: Systematic Review
Abstract: Background: Information technology can enhance timely and individual support for people with Alzheimer’s disease and other dementias and their informal carers. Objective: To review the effectiveness of technology-based counselling interventions for people with dementia and informal carers. Methods: Randomized controlled trials of remote dementia counselling interventions were included. We searched CINAHL, Cochrane Library, MEDLINE, PsycINFO, and the Web of Science Core Collection (April 2021) in combination with citation tracking and free web searching (October to November 2021). We provide meta-analyses for caregiver depression, burden, and self-efficacy/mastery and structured reporting for other outcomes. The Grading of Recommendations …Assessment, Development and Evaluation approach and the Risk of Bias 2 tool were applied. Results: We included five randomized controlled trials involving 880 participants. Interventions were provided for carers (four studies) or dyads (one study). Carers were predominantly women and were the spouses or children of people with dementia. Counselling was delivered via telephone or videoconference with two to 23 sessions over 1 to 12 months. Control groups received educational and resource materials only, standard (helpline) services, non-directive support, or home visits. Meta-analysis for our primary outcome, depressive symptoms in carers, revealed no statistically significant effect (SMD –0.15; 95% CI –0.40 to 0.10). There were also no significant effects on burden and self-efficacy/mastery. We rated the certainty of evidence as low to very low and all outcomes at an overall high risk of bias. Conclusion: The effectiveness of technology-based counselling interventions for people with dementia and informal carers remains uncertain. Theory-based approaches are needed for the development and evaluation of these interventions. Show more
Keywords: Alzheimer’s disease, counselling, dementia, information technology, remotely delivered intervention
DOI: 10.3233/JAD-221194
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 891-906, 2023
Authors: Smith, Carr J. | Ashford, J. Wesson
Article Type: Research Article
Abstract: Until 300,000 years ago, ancestors of modern humans ubiquitously carried the apolipoprotein E (APOE ) ɛ4/ɛ4 genotype, when the ɛ3 allele mutated from the ancestral ɛ4, which elevates the risk of Alzheimer’s disease. Modern humans living today predominantly carry the ɛ3 allele, which provides protection against heart disease and dementia in long-lived populations. The ancestral ɛ4 allele has been highly preserved in isolated populations in tropical and Arctic regions with high pathogen burdens, e.g., helminths. Early humans experienced serious enteric infections that exerted evolutionary selection pressure, and factors that mitigate infant and childhood mortality from enteric infections also exert selection …pressure. Some bacteria can exploit the host’s defensive inflammatory response to colonize and invade the host. Pathogen-induced inflammation associated with infant and childhood diarrhea can damage the gut wall long after the invading organisms are no longer present. Inflammation not only resides in the mucosal wall, but also induces systemic inflammation. Baseline systemic inflammation is lower in ɛ4 carriers, yet ɛ4 carriers display a stronger host inflammatory response that reduces pathogen burdens, increasing infant and early childhood survival. Evolutionary selection of the ɛ3 allele likely occurred after humans moved into temperate zones with lower pathogen burdens, unrelated to protection from Alzheimer’s disease. Show more
Keywords: Alzheimer’s disease, ɛ4 allele, enteric infections, evolution, immunity, selection
DOI: 10.3233/JAD-221218
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 907-918, 2023
Authors: Wheeler, Christopher J.
Article Type: Article Commentary
Abstract: Smith and Ashford present a compelling hypothesis on evolution of APOE alleles, namely that ɛ4 prevalence is mediated by immune selection pressure against enteric pathogens. While the ɛ3 allele is more prevalent today, it outcompetedɛ4 only relatively recently, as immune selection pressure for more effective immune responses to such pathogens was alleviated with transition to agrarian from hunter-gatherer lifestyles. Smith and Ashford’s hypothesis is intriguing in itself, but the implications for APOE ɛ4 function in Alzheimer’s disease are even more so and encourage greater focus on specific aspects of immunity in accounting for both ɛ4-mediated and general Alzheimer’s disease risk.
Keywords: Alzheimer’s disease, APOE, immunity, pathogen, selection pressure
DOI: 10.3233/JAD-230390
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 919-921, 2023
Authors: Maltais, Mathieu
Article Type: Article Commentary
Abstract: Since the last two decades, many systematic reviews and meta-analyses found contradicting results on the effect of exercise in reducing falls in people with dementia. The recently published systematic review in the Journal of Alzheimer ’s Disease found positive results in reducing falls in only two studies. The authors conclude that insufficient data remains in reducing the number of falls by exercise interventions. This commentary focuses on interdisciplinary approaches that could reduce the number of falls in this vulnerable population.
Keywords: Alzheimer’s disease, dementia, exercise, falls, prevention
DOI: 10.3233/JAD-230227
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 923-924, 2023
Authors: Dinnerstein, Eric
Article Type: Editorial
DOI: 10.3233/JAD-230254
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 925-926, 2023
Authors: Pilonieta, Giovanna | Pisu, Maria | Martin, Roy C. | Shan, Liang | Kennedy, Richard E. | Oates, Gabriela | Kim, Young-Il | Geldmacher, David S.
Article Type: Research Article
Abstract: Background: Access to specialists facilitates appropriate Alzheimer’s disease and related dementia (ADRD) medication use and adherence. However, there is little information on the impact of specialists’ availability on ADRD medication adherence, especially in regions of the United States (US) where specialists are scarce, e.g., the Deep South (DS). Objective: To ascertain whether the availability of specialty physicians in the DS and other US regions predicts ADRD medication adherence among community-dwelling older adults Methods: We conducted secondary analyses of claims data for 54,194 Medicare beneficiaries with ADRD in 2013–2015. Medication adherence was measured using the proportion of …days covered (PDC). Multivariable-adjusted Modified Poisson regression was used to examine associations of adherence with physicians’ availability by region. Results: The race/ethnicity distribution was 81.44% white, 9.17% black, 6.24% Hispanic, 2.25% Asian, and 1% other; 71.81% were female, and 42.36% were older than 85 years. Beneficiaries across regions differed in all individual and contextual characteristics except sex and comorbidities. Neurologists and psychiatrists’ availability was not significantly associated with adherence (DS = 1.00, 0.97–1.03 & non-DS = 1.01, 1.00–1.01). Race and having ≥1 specialist visits were associated with a lower risk of adherence in both regions (p < 0.0001). Advanced age, dual Medicare/Medicaid eligibility, and living in non-large metropolitan areas, were associated with adherence in the non-DS region. Conclusion: Among older Americans with ADRD, a context defined by specialist availability does not affect adherence, but other context characteristics related to socioeconomic status may. Research should further examine the influence of individual and contextual factors on ADRD treatment among older adults. Show more
Keywords: Alzheimer’s disease, medication adherence, Medicare, physician availability, specialist use, socioeconomic factors
DOI: 10.3233/JAD-220620
Citation: Journal of Alzheimer's Disease, vol. 93, no. 3, pp. 927-937, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]